Windtree Therapeutics, Inc.
WINT
$1.20
-$0.10-7.69%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 74.51% | -26.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.60% | 159.98% | |||
| Operating Income | 58.60% | -159.98% | |||
| Income Before Tax | 74.73% | -214.46% | |||
| Income Tax Expenses | -221.83% | 72.81% | |||
| Earnings from Continuing Operations | 77.14% | -217.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.14% | -217.66% | |||
| EBIT | 58.60% | -159.98% | |||
| EBITDA | 58.71% | -159.31% | |||
| EPS Basic | 79.78% | -- | |||
| Normalized Basic EPS | 83.23% | -- | |||
| EPS Diluted | 79.78% | -- | |||
| Normalized Diluted EPS | 83.23% | -- | |||
| Average Basic Shares Outstanding | 54.26% | -- | |||
| Average Diluted Shares Outstanding | 54.26% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
